World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 88 13249 12472 6748 6242 463 26024

Xuemei Wang publications per year

The chart shows the history of publications by Xuemei Wang between 2001 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Xuemei Wang published across 26 years, from 2001 to 2026, averaging 20.6 papers a year. Output peaked at 44 publications in 2023. 13 of the 535 publications appeared in the last two years.

No. of publications
10 20 30 40
Bar chart. Horizontal axis: year, 2001 to 2026. Vertical axis: number of publications, 0 to 44. Peak 44 publications in 2023. 2001: 9 publications 2002: 8 publications 2003: 6 publications 2004: 8 publications 2005: 6 publications 2006: 18 publications 2007: 13 publications 2008: 19 publications 2009: 18 publications 2010: 17 publications 2011: 19 publications 2012: 27 publications 2013: 21 publications 2014: 19 publications 2015: 23 publications 2016: 38 publications 2017: 32 publications 2018: 36 publications 2019: 40 publications 2020: 27 publications 2021: 40 publications 2022: 23 publications 2023: 44 publications 2024: 11 publications 2025: 12 publications 2026: 1 publication
2001 2026

535 publications in total across all disciplines

View publications per year as a table
Xuemei Wang: publications per year, 2001 to 2026
Year Publications
2001 9
2002 8
2003 6
2004 8
2005 6
2006 18
2007 13
2008 19
2009 18
2010 17
2011 19
2012 27
2013 21
2014 19
2015 23
2016 38
2017 32
2018 36
2019 40
2020 27
2021 40
2022 23
2023 44
2024 11
2025 12
2026 1
Total 535
Download as CSV

Xuemei Wang publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Xuemei Wang sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 461–480 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 463 publications — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751 463
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Xuemei Wang D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Xuemei Wang sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 88–89 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970 88
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Xuemei Wang is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medical and oncological fields, contributing extensively to several subfields such as pulmonary and respiratory medicine, hematology, oncology, surgery, and genetics.

The main topics of Wang's work include acute myeloid leukemia research, gastric cancer management and outcomes, chronic lymphocytic leukemia research, prostate cancer treatment and research, chronic myeloid leukemia treatments, prostate cancer diagnosis and treatment, and colorectal cancer treatments and studies.

Wang has published numerous papers in high-profile journals. Some selected recent publications are:

  • Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study, 2021, Journal for ImmunoTherapy of Cancer
  • Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia, 2022, Journal of Clinical Oncology
  • Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia, 2021, JAMA Oncology
  • Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy, 2022, Blood Cancer Journal
  • The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development, 2020, Clinical Cancer Research

Wang collaborates frequently with several other researchers, including:

  • Hagop M. Kantarjian
  • Tapan M. Kadia
  • Naveen Pemmaraju
  • Nitin Jain
  • Courtney D. DiNardo

Their work is often published in journals such as Blood, Journal of Clinical Oncology, American Journal of Hematology, The Journal of Urology, and Oncology.

Wang has contributed significantly to the field of medicine, with 247 publications primarily related to their main area of expertise. The subfields reflect focused investigations into respiratory and hematologic conditions, surgical interventions, and genetic factors influencing disease.

Best Publications

  • Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

    Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang

  • Body surface area and body weight predict total liver volume in Western adults

    Jean Nicolas Vauthey;Eddie K. Abdalla;Dorota A. Doherty;Philippe Gertsch

  • Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

    Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang

  • Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

    Christos N. Papandreou;Danai D. Daliani;Darrell Nix;Hong Yang

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

    William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl

  • Fingerprinting the circulating repertoire of antibodies from cancer patients

    Paul J. Mintz;Jeri Kim;Kim Anh Do;Xuemei Wang

  • Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility.

    Milena S. Nicoloso;Hao Sun;Hao Sun;Riccardo Spizzo;Hyunsoo Kim

  • Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.

    Melanie B. Thomas;Romil Chadha;Katrina Glover;Xuemei Wang

  • PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    Filip Janku;Apostolia Maria Tsimberidou;Ignacio Garrido-Laguna;Xuemei Wang

  • Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy.

    Philippe E. Spiess;Andrew K. Lee;Dan Leibovici;Xuemei Wang

  • The Crosstalk of mTOR/S6K1 and Hedgehog Pathways

    Yan Wang;Qingqing Ding;Chia Jui Yen;Weiya Xia

  • Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

    Nizar M. Tannir;Eric Jonasch;Laurence Albiges;Emre Altinmakas

  • Guidelines for Reporting of Statistics for Clinical Research in Urology.

    Melissa Assel;Daniel Sjoberg;Andrew Elders;Xuemei Wang

  • High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

    Stefan O. Ciurea;Marcos J.G. de Lima;Pedro Cano;Martin Korbling

  • Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate

    Christos N. Papandreou;Danai D. Daliani;Peter F. Thall;Shi Ming Tu

  • Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

    Min S. Park;Shreyaskumar R. Patel;Joseph A. Ludwig;Jonathan C. Trent

  • Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

    Borje S. Andersson;Peter F. Thall;Timothy Madden;Daniel Couriel

  • Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

    Ana M. Aparicio;Li Shen;Elsa M Li Ning Tapia;Jing-Fang Lu

  • Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance

    Taghi Manshouri;Kim Anh Do;Xuemei Wang;Francis J. Giles

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Jaffer A. Ajani
Jaffer A. Ajani The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine often means exploring versatile pathways and continued education options. Many students are now turning to online programs for added flexibility and diverse opportunities within the healthcare field.

For those interested in healthcare administration, top cahme-accredited mha programs offer rigorous online curricula and accreditation, essential for leadership roles in hospitals and clinics.

Nurses seeking to advance their credentials can look into online rn to bsn programs without clinicals. These options are ideal for working professionals who want to deepen their knowledge without the additional scheduling challenges of in-person clinical rotations.

Aspiring nurse practitioners and leaders might consider the fastest online dnp programs, enabling them to reach the highest level of nursing practice in less time.

For those who prefer a more streamlined doctoral experience, some dnp programs without dissertation offer an accelerated path, focusing on practical leadership rather than traditional research.

Best Scientists Citing Xuemei Wang

Trending Scientists

Recently Published Articles